AG
BPMC

Algert Global’s Blueprint Medicines BPMC Stock Holding History

Algert Global’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-68,420
Closed -$6.06M – 1189
2025
Q1 		$6.06M Sell
68,420
-43,752
-39% -$4.27M 0.15% 214
2024
Q4 		$9.78M Buy
112,172
+19,936
+22% +$1.83M 0.23% 115
2024
Q3 		$8.53M Buy
92,236
+26,696
+41% +$2.65M 0.23% 110
2024
Q2 		$7.06M Buy
65,540
+29,330
+81% +$2.94M 0.23% 109
2024
Q1 		$3.44M Buy
36,210
+12,280
+51% +$1.05M 0.13% 258
2023
Q4 		$2.21M Buy
23,930
+17,970
+302% +$1.16M 0.09% 379
2023
Q3 		$299K Buy
+5,960
New +$318K 0.01% 896
2022
Q3 		– Sell
-11,819
Closed -$597K – 1185
2022
Q2 		$597K Buy
11,819
+1,050
+10% +$61.5K 0.04% 695
2022
Q1 		$688K Buy
10,769
+1,457
+16% +$105K 0.05% 688
2021
Q4 		$997K Buy
9,312
+6,394
+219% +$669K 0.12% 281
2021
Q3 		$300K Buy
+2,918
New +$272K 0.04% 763
2020
Q3 		– Sell
-10,813
Closed -$843K – 407
2020
Q2 		$843K Sell
10,813
-14,950
-58% -$1.01M 0.29% 126
2020
Q1 		$1.51M Buy
+25,763
New +$1.66M 0.64% 23
2018
Q4 		– Sell
-5,722
Closed -$447K – 374
2018
Q3 		$447K Buy
+5,722
New +$398K 0.1% 262

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Algert Global's BPMC Position: Q2 2025 in Review

Algert Global sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 68,420 shares — an estimated $6.06M sold.

Algert Global first reported a position in BPMC in Q3 2018 and held it in 14 quarters. The position peaked at $9.78M in Q4 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Algert Global reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Algert Global sold 68,420 Blueprint Medicines shares in Q2 2025, an estimated $6.06M.
  • Algert Global first reported a position in Blueprint Medicines in Q3 2018 and held it in 14 quarters.
  • Algert Global's Blueprint Medicines position peaked at $9.78M in Q4 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Algert Global's 13F filing for Q2 2025, filed 14 Aug 2025.